全文获取类型
收费全文 | 225643篇 |
免费 | 57292篇 |
国内免费 | 643篇 |
专业分类
耳鼻咽喉 | 3992篇 |
儿科学 | 8116篇 |
妇产科学 | 3262篇 |
基础医学 | 34836篇 |
口腔科学 | 8589篇 |
临床医学 | 29311篇 |
内科学 | 53036篇 |
皮肤病学 | 10045篇 |
神经病学 | 25666篇 |
特种医学 | 7749篇 |
外国民族医学 | 10篇 |
外科学 | 37807篇 |
综合类 | 2281篇 |
现状与发展 | 2篇 |
一般理论 | 125篇 |
预防医学 | 18134篇 |
眼科学 | 4338篇 |
药学 | 17257篇 |
1篇 | |
中国医学 | 1179篇 |
肿瘤学 | 17842篇 |
出版年
2023年 | 1216篇 |
2022年 | 1451篇 |
2021年 | 4167篇 |
2020年 | 7175篇 |
2019年 | 13168篇 |
2018年 | 13247篇 |
2017年 | 13788篇 |
2016年 | 14652篇 |
2015年 | 14821篇 |
2014年 | 15984篇 |
2013年 | 18072篇 |
2012年 | 11508篇 |
2011年 | 11847篇 |
2010年 | 13369篇 |
2009年 | 9703篇 |
2008年 | 8833篇 |
2007年 | 7924篇 |
2006年 | 7779篇 |
2005年 | 7630篇 |
2004年 | 7167篇 |
2003年 | 6709篇 |
2002年 | 6655篇 |
2001年 | 5005篇 |
2000年 | 5101篇 |
1999年 | 4289篇 |
1998年 | 2020篇 |
1997年 | 1680篇 |
1996年 | 1715篇 |
1995年 | 1477篇 |
1994年 | 1396篇 |
1993年 | 1244篇 |
1992年 | 3109篇 |
1991年 | 2940篇 |
1990年 | 2756篇 |
1989年 | 2817篇 |
1988年 | 2628篇 |
1987年 | 2527篇 |
1986年 | 2403篇 |
1985年 | 2345篇 |
1984年 | 1965篇 |
1983年 | 1702篇 |
1982年 | 1168篇 |
1981年 | 953篇 |
1979年 | 1546篇 |
1978年 | 1159篇 |
1977年 | 992篇 |
1975年 | 900篇 |
1974年 | 1052篇 |
1973年 | 931篇 |
1972年 | 911篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
2.
3.
Isolated patellofemoral arthritis is an increasingly recognized entity, and is usually associated with previous patellofemoral dysplasia or instability. Patellofemoral arthroplasty (PFA) has evolved significantly in recent years, both in terms of implant design and importantly in the understanding of appropriate patient selection. This review outlines the indications and investigations for PFA, provides a brief history of the development of contemporary implants, and presents the clinical outcomes for the prostheses most commonly used in the UK. In addition, it provides a detailed surgical technique for implantation of an onlay implant, with tips on how to optimize patellofemoral biomechanics and thus achieve a consistently good outcome. 相似文献
4.
5.
6.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
7.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
8.
9.
10.